Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as...
查看详情July 25, 2018-- Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that dosing has begun ina ...
In March 2018, BAT4306F, the recombinant glycosylation-modified anti-human-CD20 monoclonal antibody solution for injecti...
GUANGZHOU, CHINA, March 29, 2018 – Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline...
